Sunovion is determined to help people breathe easy and sleep properly, among other things. The pharmaceutical company focuses its drug development efforts in two main therapeutic categories: respiratory and central nervous system (CNS) disorders. Among its marketed products are asthma drug Xopenex, insomnia therapy Lunesta, schizophrenia treatment Latuda, and Brovana, a chronic obstructive pulmonary disease (COPD) treatment. Sunovion markets its products to primary care physicians and some specialists in the US. Sunovion is a subsidiary of Japanese firm Sumitomo Dainippon Pharma.
The company's portfolio of brands includes Aptiom, Amnaris, Latuda, Lunesta, Xopenex, Brovana, Zetonna, and Alvesco. It also has drugs in testing phase for such ailments as binge eating disorder.
Sunovion, owned by a Japanese parent, is based in the US and serves physicians nationwide.
Sales and Marketing
Sunovion markets its products to primary care doctors and such specialists as allergists and sleep doctors. Its main customers are drug wholesalers McKesson, Cardinal Health, and AmerisourceBergen; the company also sells directly to pharmacy chains and home health care firms.
To ensure its long-term success, Sunovion develops new drugs (and improves on already-marketed ones) in its focus areas of respiratory disease and CNS disorders. Drug candidates in the works include possible treatments for depression and anxiety. The FDA in 2015 approved its supplemental New Drug Application (sNDA) for Aptiom as a monotherapy for the treatment of partial-onset seizures. In 2014 Sunovion partnered with Afraxis to leverage the enhanced spin platform the company developed as a way to speed Sunovion's preclinical CNS drug discovery process.
Also that year, the firm sold certain rights to its Xopenex Inhalation Solution for $45 million; it retained rights to sell Xopenex HFA Inhalation Aerosol, a different formulation of the product.
Mergers and Acquisitions
In October 2016 Sunovian acquired Toronto-based Cynapsus Therapeutics for $624 million. The addition of Cynapsus, which is developing a treatment for complications from Parkinson's disease, expanded Sunovion's neurology portfolio.
While Sunovion traces its roots back to 1984, the company reached profitability as recently as 2005, the year it introduced Lunesta. Each year Lunesta became more important to the company's sales, and by 2009 accounted for about half of its revenue. Looking to expand Lunesta outside of North America and into Asia, Sunovion agreed to be purchased by DSP in 2009. (The company had already been pursuing regulatory approval for Lunesta in international markets through partnerships with other drugmakers.)